NO20032678L - NMDA reseptor agonist farmasöytiske sammensetninger - Google Patents

NMDA reseptor agonist farmasöytiske sammensetninger

Info

Publication number: NO20032678L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; receptor agonist; nmda receptor; agonist pharmaceutical; nmda
Prior art date: 2000-12-13

Application number

NO20032678A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032678D0 (no

Inventor

Jinyang Hong

Yesook Kim

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2003-06-12

Publication date

2003-06-12

2003-06-12 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-06-12 Publication of NO20032678L publication Critical patent/NO20032678L/no

2003-06-12 Publication of NO20032678D0 publication Critical patent/NO20032678D0/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Psychology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO20032678A 2000-12-13 2003-06-12 NMDA reseptor agonist farmasöytiske sammensetninger NO20032678D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en)	2000-12-13	2001-12-05	Nmda receptor agonist pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
NO20032678L true NO20032678L (no)	2003-06-12
NO20032678D0 NO20032678D0 (no)	2003-06-12

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032678A NO20032678D0 (no)	2000-12-13	2003-06-12	NMDA reseptor agonist farmasöytiske sammensetninger

Country Status (41)

Country	Link
US (2)	US6635270B2 (xx)
EP (1)	EP1347760B1 (xx)
JP (1)	JP2004515529A (xx)
KR (1)	KR100533407B1 (xx)
CN (1)	CN1273135C (xx)
AP (1)	AP1235A (xx)
AR (1)	AR035607A1 (xx)
AT (1)	ATE296629T1 (xx)
AU (2)	AU1845402A (xx)
BG (1)	BG107788A (xx)
BR (1)	BR0116085A (xx)
CA (1)	CA2431172A1 (xx)
CZ (1)	CZ20031543A3 (xx)
DE (1)	DE60111265T2 (xx)
DO (1)	DOP2001000300A (xx)
DZ (1)	DZ3484A1 (xx)
EA (1)	EA006489B1 (xx)
EC (1)	ECSP034655A (xx)
EE (1)	EE200300284A (xx)
ES (1)	ES2239648T3 (xx)
GE (1)	GEP20053568B (xx)
HR (1)	HRP20030473A2 (xx)
HU (1)	HUP0400645A2 (xx)
IL (1)	IL155810A0 (xx)
IS (1)	IS6811A (xx)
MA (1)	MA26970A1 (xx)
MX (1)	MXPA03005257A (xx)
NO (1)	NO20032678D0 (xx)
NZ (1)	NZ525742A (xx)
OA (1)	OA12414A (xx)
PA (1)	PA8534901A1 (xx)
PE (1)	PE20020710A1 (xx)
PL (1)	PL362080A1 (xx)
PT (1)	PT1347760E (xx)
SK (1)	SK6982003A3 (xx)
TN (1)	TNSN01173A1 (xx)
UA (1)	UA73619C2 (xx)
UY (1)	UY27068A1 (xx)
WO (1)	WO2002047685A2 (xx)
YU (1)	YU41103A (xx)
ZA (1)	ZA200303892B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1615646B2 (en)	2003-04-08	2022-07-27	Progenics Pharmaceuticals, Inc.	Pharmaceutical formulations containing methylnaltrexone
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
AR063984A1 (es) *	2006-11-28	2009-03-04	Wyeth Corp	Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
TW200901974A (en) *	2007-01-16	2009-01-16	Wyeth Corp	Compounds, compositions, and methods of making and using them
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
BRPI0918868B8 (pt)	2008-09-18	2021-05-25	Naurex Inc	compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en)	2010-02-11	2015-08-11	Northwestern University	Secondary structure stabilized NMDA receptor modulators and uses thereof
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
EA032153B1 (ru)	2013-01-29	2019-04-30	Аптиникс Инк.	Спиролактамные модуляторы nmda-рецептора и их применение
AU2014212487C1 (en)	2013-01-29	2018-10-25	Aptinyx, Inc.	Spiro-lactam NMDA receptor modulators and uses thereof
PE20151438A1 (es)	2013-01-29	2015-10-10	Naurex Inc	Moduladores de receptores nmda de espiro-lactama y sus usos
AU2014212484B2 (en)	2013-01-29	2018-01-04	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam NMDA receptor modulators and uses thereof
KR20150110784A (ko)	2013-01-29	2015-10-02	노렉스, 인크.	스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2015099381A1 (ko) *	2013-12-23	2015-07-02	주식회사 삼양바이오팜	팔로노세트론을 함유하는 약학 조성물
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es)	2016-05-19	2019-02-01	Aptinyx Inc	Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
PE20190504A1 (es)	2016-08-01	2019-04-10	Aptinyx Inc	Moduladores del receptor nmda espiro-lactam y uso de los mismos
EP3490992B1 (en)	2016-08-01	2023-03-22	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en)	2016-08-01	2019-02-27	Aptinyx Inc	Spiro-lactam nmda receptor modulators and uses thereof
EA201990425A1 (ru)	2016-08-01	2019-08-30	Аптиникс Инк.	Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
CN109843889B (zh)	2016-08-01	2022-03-15	阿普廷伊克斯股份有限公司	螺-内酰胺nmda调节剂和使用其的方法
CA3089561A1 (en)	2018-01-31	2019-08-08	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en)	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en)	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
ES2170857T3 (es) *	1995-08-11	2002-08-16	Pfizer	Metanosulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol trihidrato.
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Ceased
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678D0/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20030070060A (ko)	2003-08-27
DE60111265D1 (de)	2005-07-07
UA73619C2 (en)	2005-08-15
US20040039022A1 (en)	2004-02-26
JP2004515529A (ja)	2004-05-27
TNSN01173A1 (fr)	2005-11-10
HUP0400645A2 (hu)	2004-06-28
CA2431172A1 (en)	2002-06-20
AR035607A1 (es)	2004-06-16
IL155810A0 (en)	2003-12-23
WO2002047685A2 (en)	2002-06-20
EP1347760B1 (en)	2005-06-01
MXPA03005257A (es)	2003-09-25
US20020111366A1 (en)	2002-08-15
KR100533407B1 (ko)	2005-12-02
EE200300284A (et)	2003-10-15
EA006489B1 (ru)	2005-12-29
AU2002218454B2 (en)	2005-10-27
EP1347760A2 (en)	2003-10-01
ATE296629T1 (de)	2005-06-15
ES2239648T3 (es)	2005-10-01
PL362080A1 (en)	2004-10-18
BG107788A (bg)	2004-01-30
PT1347760E (pt)	2005-09-30
NO20032678D0 (no)	2003-06-12
NZ525742A (en)	2005-07-29
CZ20031543A3 (cs)	2004-06-16
DZ3484A1 (fr)	2002-06-20
UY27068A1 (es)	2002-07-31
DOP2001000300A (es)	2002-05-30
ZA200303892B (en)	2004-05-20
YU41103A (sh)	2006-05-25
AP1235A (en)	2004-01-06
EA200300514A1 (ru)	2003-10-30
IS6811A (is)	2003-05-08
US6635270B2 (en)	2003-10-21
AP2001002376A0 (en)	2001-12-31
ECSP034655A (es)	2003-07-25
CN1479617A (zh)	2004-03-03
DE60111265T2 (de)	2006-05-04
BR0116085A (pt)	2003-12-23
HRP20030473A2 (en)	2005-04-30
GEP20053568B (en)	2005-07-11
SK6982003A3 (en)	2004-08-03
OA12414A (en)	2006-04-18
MA26970A1 (fr)	2004-12-20
AU1845402A (en)	2002-06-24
HK1059575A1 (en)	2004-07-09
WO2002047685A3 (en)	2002-08-15
PE20020710A1 (es)	2002-08-09
PA8534901A1 (es)	2002-08-26
CN1273135C (zh)	2006-09-06

Publication	Publication Date	Title
NO20032678D0 (no)	2003-06-12	NMDA reseptor agonist farmasöytiske sammensetninger
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
FI20105657L (fi)	2010-06-10	Farmaseuttisia koostumuksia
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
ATE431145T1 (de)	2009-05-15	Missbrauchssichere orale opioid-agonist zubereitungen
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
NO20030418D0 (no)	2003-01-27	Nytt farmasöytisk preparat
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
DE60122495D1 (de)	2006-10-05	TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DK1068202T3 (da)	2009-03-16	1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
IL161997A0 (en)	2005-11-20	Pharmaceutical composition comprising a 5ht1 receptor agonist
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
MA26890A1 (fr)	2004-12-20	Metabolites agonistes/ antagonistes d'oestrogenes
NO20031095D0 (no)	2003-03-10	Farmasöytiske sammensetninger
DK1347760T3 (da)	2005-09-05	Farmaceutiske kompositioner med NMDA receptor agonister
EE200200689A (et)	2004-06-15	Ravimkoostised
DK1450770T3 (da)	2005-08-01	Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
SE0003996D0 (sv)	2000-11-01	Receptorantagonister

Legal Events

Date	Code	Title	Description
2008-07-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application